Chiaroscuro hematopoietic stem cell
Animals; Cell Differentiation; Cytokines; Female; Gene Therapy; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred BALB C; Models, Biological; Phenotype
Life Sciences | Medicine and Health Sciences
These observations suggest several immediate clinical strategies. In gene therapy, approaches could be targeted to obtain cycling of hematopoietic stem cells and gene-carrying retrovirus vector integration followed by engraftment at an appropriate time interval which favors engraftment. The same type of approach can be utilized for stem cell expansion approaches. Alternatively marrow or peripheral stem cell engraftment can be obtained with minimal to no toxicity in allochimeric strategies in such diseases as sickle cell anemia or thalassemia. A similar approach could be useful in obtaining cell engraftment with minimal toxicity in therapies employing cellular immune (T-cell and NK-cell) attack against cancer. These areas of clinical application are outline in Table 3.
Rights and Permissions
Citation: Trans Am Clin Climatol Assoc. 1998;109:19-25; discussion 25-6.
Transactions of the American Clinical and Climatological Association
Quesenberry, Peter J.; Habibian, Houri K.; Dooner, Mark S.; Zhong, Suju; Reilly, Judith; Peters, Stefan O.; Becker, Pamela S.; Grimaldi, Christina I.; Carlson, Jane E.; Reddy, G. Prem Veer; Nilsson, Susan K.; and Stewart, F. Marc, "Chiaroscuro hematopoietic stem cell" (1998). Open Access Articles. 1681.